Indiana 2024 Regular Session

Indiana House Bill HB1259

Introduced
1/9/24  
Refer
1/9/24  
Report Pass
1/23/24  
Engrossed
1/30/24  
Refer
2/5/24  
Report Pass
2/15/24  
Enrolled
2/21/24  
Passed
3/13/24  
Chaptered
3/13/24  

Caption

Health care matters.

Impact

If enacted, the bill will introduce new compliance measures for pharmacy benefit managers, requiring them to disclose certain information regarding audits and claims data. It will also create a therapeutic psilocybin research fund that grants financial assistance to research institutions for clinical studies on psilocybin's therapeutic benefits. This measure aims to encourage research into alternative treatment options for mental health, possibly making psilocybin a legitimate component of mental health therapy.

Summary

House Bill 1259 focuses on healthcare matters in the State of Indiana, particularly around regulations concerning pharmacy benefit managers and the use of psilocybin for therapeutic purposes. The bill aims to enhance transparency and accountability among healthcare providers and benefit managers while establishing a fund for psilocybin research to assess its efficacy in treating various mental health conditions. This includes conditions such as PTSD, anxiety, and depression, particularly among veterans and first responders. This potentially marks a significant shift in the state's approach to mental health treatments.

Sentiment

Overall sentiment around HB 1259 appears to be cautiously optimistic from supporters, particularly among those advocating for mental health advancements. However, there may be some contention related to the implementation of new auditing requirements and the implications for pharmacy groups. Advocates of psilocybin research express enthusiasm for its potential benefits, while opponents may raise concerns about the safety and ethical considerations surrounding psychedelic treatments.

Contention

Key points of contention involve the balance between increased regulatory oversight of pharmacy benefit managers and their operational abilities. Critics may argue that the new compliance mandates could hinder flexibility and efficiency within the healthcare sector. Additionally, while psilocybin research is promising, there are likely ongoing debates on its regulation and acceptance within the broader medical community, reflecting concerns about safety and adherence to existing medical practices.

Companion Bills

No companion bills found.

Similar Bills

IN HB1004

Health care matters.

CA SB306

Sexually transmitted disease: testing.

CA SB1191

Medi-Cal: pharmacogenomic testing.

CA AB114

Medi-Cal benefits: rapid Whole Genome Sequencing.

NV AB186

Revises provisions governing pharmacists. (BDR 54-344)

CA AB1929

Medi-Cal benefits: violence prevention services.

IL SB3268

DHFS-FUND TRANSFERS

MS HB791

Pharmacists; authorize to test for and administer treatment for minor, nonchronic health conditions.